Antidepressants, well-being and survival in advanced cancer. The ZEST Trial: A double-blind, placebo-controlled trial of Zoloft's Effects on Symptoms and survival Time in Advanced Cancer
A double-blind, placebo-controlled trial of Zoloft's Effects on Symptoms and survival Time in Advanced Cancer
CTC
440 participants
May 1, 2002
Interventional
Conditions
Summary
Symptoms of depression, anxiety, fatigue and lack of energy are common, important and closely related in people with advanced cancer. Modern antidepressants are highly effective at relieving these symptoms in people WITH clinical depression. This study will determine if a modern antidepressant can improve these symptoms in people with advanced cancer but WITHOUT clinical depression. Patients are randomized to receive either sertraline 50mg daily or placebo. Oncological, psychological, psychiatric, social and other support services are used according to standard best practice at that centre. Participants complete quality of life booklets and are reviewed at months 0, 1, 2, 3, 4, 6, 9, and 12.
Eligibility
Inclusion Criteria1
- Advanced cancer defined by the presence of metastatic disease and treatment with palliative intent, that is to improve length and quality of life, but without realistic hope of cure. 2.Symptomatic: score >= 4/10 for depression, anxiety, fatigue or lack of energy at baseline. 3.ECOG performance status 0-2. 4.Life expectancy of >3 months. 5.Serum creatinine <200 micromol/L and bilirubin <30micromol/L within 28 days of randomization. 6.Able to complete baseline quality of life instruments. 7.Availability and willingness for follow-up. 8.Written informed consent. 9.Women of childbearing potential must be taking adequate contraceptive precautions.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
ARM A. Sertraline 50mg tablets. One tablet once a day by mouth.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000381684